OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Methods & Clinical Development is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD	220
Oncolytic Viruses and the Immune System: The Dynamic Duo	149
Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy	120
The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19	108
Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies	87
Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors	82
CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain	76
Adeno-Associated Viral Vectors in Neuroscience Research	74
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial	74
Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning	72
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease	65
Circular RNAs: Promising Molecular Biomarkers of Human Aging-Related Diseases via Functioning as an miRNA Sponge	65
Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection	63
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice	62
Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media	60
Use of Nanovesicles from Orange Juice to Reverse Diet-Induced Gut Modifications in Diet-Induced Obese Mice	60
Immune Response Mechanisms against AAV Vectors in Animal Models	57
AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria	56
Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?	53
Comparison of analytical techniques to quantitate the capsid content of adeno-associated viral vectors	53
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene	52
Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles	51
qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies	48
Creation of a High-Yield AAV Vector Production Platform in Suspension Cells Using a Design-of-Experiment Approach	48
Acerola exosome-like nanovesicles to systemically deliver nucleic acid medicine via oral administration	47

Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System	45
Development of Large-Scale Downstream Processing for Lentiviral Vectors	43
Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells	41
Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection	40
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways	40
Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design	40
AAV-Genome Population Sequencing of Vectors Packaging CRISPR Components Reveals Design-Influenced Heterogeneity	39
High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models	39
AAV-S: A versatile capsid variant for transduction of mouse and primate inner ear	39
Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy	39
Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9	38
Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice	38
In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy	37
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells	37